Table 3.
Number of tissue HER-2-negative patients with elevated or normal serum HER-2, cfHER-2 DNA and cfB2M DNA levels prior to metastases detection
| Serum HER-2 prior to metastases detection (tissue-negative) | With metastases | Without metastases | Total |
| Elevated | 4 | 11 | 15 |
| Normal | 6 | 29 | 35 |
| Total | 10 | 40 | 50 |
| CfHER-2 DNA prior to metastases detection (tissue-negative) | With metastases | Without metastases | Total |
| Elevated | 4 | 6 | 10 |
| Normal | 6 | 34 | 40 |
| Total | 10 | 40 | 50 |
| CfB2M DNA prior to metastases detection (tissue-negative) | With metastases | Without metastases | Total |
| Elevated | 3 | 4 | 7 |
| Normal | 7 | 36 | 43 |
| Total | 10 | 40 | 50 |